Company Reinforces Leadership Position for Mass Spectrometry-Based Quantitation

AB Sciex marked the one-year anniversary of the introduction of the AB Sciex 6500 series in June by bringing together more than a thousand mass spectrometry users to share insight, data and experiences with what has now become the industry’s top-selling, high-end triple quadrupole.

Responding to growing market demand for next-generation technology for quantitation, AB Sciex revealed brand new data on the 6500 series at its Users Meeting, just hours before the start of the American Society for Mass Spectrometry (ASMS) conference.

The 6500 system is a high-performance triple quadrupole with high sensitivity. Differentiating this instrumentation is the QTRAP® version for integrated quantitative and qualitative analysis as well as SelexION™ Differential Mobility Separation Technology, which adds yet another dimension of selectivity for analysing complex samples.

Among the customers who have adopted the QTRAP® 6500 system for quantitation, along with the TripleTOF® 5600 System for discovery, is Jenny Van Eyk, a Senior Researcher at Johns Hopkins University. Dr Van Eyk spoke at the AB Sciex Users Meeting about her collaborative work with AB Sciex to develop automated workflows for targeted quantitative proteomics.

Focused on advancing heart and vascular disease research, Dr Van Eyk is seeking to identify and validate new markers to potentially bring into the clinic someday. In addition to a large discovery program, she is analysing thousands of samples in her validating program to assess which protein targets could have the most clinical utility. The 6500 system is an ideal instrument for her type of research.

The AB Sciex Users Meeting focused on celebrating the success of hundreds of customers, including over 30 scientists who were presenting. Like Dr Van Eyk, these customers have been able to advance their scientific pursuits through the use of the 6500 system as well as other AB Sciex platforms. Among the speakers were: Ruedi Aebersold (ETH Zurich); Jeffrey Whiteaker (Fred Hutchinson Cancer Research Center); Paul Moench (Novartis); Brendon Kapinos (Pfizer); Mingshe Zhu (Bristol Myers Squibb); Todd Mitchell (University of Wollongong); among 20+ others.